Welcome to our dedicated page for Medtech Acquisition news (Ticker: MTACU), a resource for investors and traders seeking the latest updates and insights on Medtech Acquisition stock.
Medtech Acquisition Corp (MTACU) provides investors with timely updates on its mission to identify and merge with innovative healthcare technology companies. This page serves as the definitive source for MTACU-related developments, offering curated access to press releases, regulatory filings, and strategic announcements.
Track the SPAC's progress through key milestones including merger target evaluations, shareholder voting updates, and post-acquisition integration plans. Our repository ensures equal access to material disclosures about capital deployment strategies and leadership decisions shaping MTACU's trajectory in the medtech sector.
Discover updates across three core areas: transaction announcements detailing potential mergers, financial communications reflecting SEC filings, and operational developments impacting the company's SPAC lifecycle. Content is rigorously verified against primary sources to maintain accuracy.
Bookmark this page for streamlined monitoring of MTACU's activities in medical technology innovation. Check back regularly for unfiltered access to the information driving investment decisions in this specialized acquisition vehicle.
TriSalus Life Sciences has announced new Phase 1 clinical data at the AACR 2023 Annual Meeting regarding its Pressure-Enabled Regional Immuno-Oncology (PERIO-01) trial for uveal melanoma with liver metastases. The trial, utilizing the investigational drug SD-101 delivered via the TriNav Infusion System, aims to enhance systemic checkpoint inhibitors' effectiveness. Of 27 enrolled patients, treatment-related adverse events were mostly non-serious, with one significant event reported. Encouragingly, ctDNA and circulating tumor cell levels decreased in several patients, indicating potential improved survival outcomes. TriSalus is preparing for a business combination with MedTech Acquisition Corporation (MTAC), projected to list under the ticker TLSI, pending necessary approvals.
TriSalus Life Sciences announced the appointment of Jim Alecxih as President of Device Technology Business. With over 30 years of experience in product development and commercialization, Alecxih will oversee the growth of the TriNav Infusion System, which has been used in over 17,000 procedures. The Company is in the process of going public through a merger with MedTech Acquisition Corporation (ticker: MTAC) expected to close in Q2 2023, pending shareholder approval. TriSalus aims to disrupt cancer treatment for liver and pancreatic tumors through innovative drug delivery technology.
